Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NPH012
MIFTS: 59

Nephrotic Syndrome

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Immune diseases, Metabolic diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Nephrotic Syndrome

About this section

MalaCards integrated aliases for Nephrotic Syndrome:

Name: Nephrotic Syndrome 12 76 37 29 55 6 44 15 40 73
Finnish Congenital Nephrotic Syndrome 73

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Metabolic diseases
Anatomical: Nephrological diseases Blood diseases Endocrine diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1184
ICD10 33 N04 N04.9
ICD9CM 35 581
MeSH 44 D009404
NCIt 50 C34845
SNOMED-CT 68 52254009
KEGG 37 H01657
Sources

Summaries for Nephrotic Syndrome

About this section
Disease Ontology : 12 A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability.

MalaCards based summary : Nephrotic Syndrome, also known as finnish congenital nephrotic syndrome, is related to nephrotic syndrome, type 1 and familial nephrotic syndrome, and has symptoms including edema An important gene associated with Nephrotic Syndrome is NPHS2 (NPHS2, Podocin), and among its related pathways/superpathways are Interferon gamma signaling and Hexose transport. The drugs Mycophenolic acid and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Nephrotic syndrome is a collection of symptoms due to kidney damage. This includes protein in the urine,... more...

Sources

Related Diseases for Nephrotic Syndrome

About this section

Diseases in the Nephrotic Syndrome family:

Nephrotic Syndrome, Type 1 Nephrotic Syndrome, Type 4
Nephrotic Syndrome, Type 2 Nephrotic Syndrome, Type 3
Nephrotic Syndrome, Type 6 Nephrotic Syndrome, Type 7
Nephrotic Syndrome, Type 8 Nephrotic Syndrome, Type 9
Nephrotic Syndrome, Type 10 Nephrotic Syndrome, Type 11
Nephrotic Syndrome, Type 12 Nephrotic Syndrome, Type 13
Nephrotic Syndrome, Type 14 Nephrotic Syndrome, Type 15
Nephrotic Syndrome, Type 16 Familial Nephrotic Syndrome

Diseases related to Nephrotic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 637)
# Related Disease Score Top Affiliating Genes
1 nephrotic syndrome, type 1 34.3 NPHS1 NPHS2 WT1
2 familial nephrotic syndrome 34.1 NPHS1 NPHS2 PLCE1 WT1
3 lipoid nephrosis 33.7 ALB NPHS1 NPHS2
4 pierson syndrome 33.6 LAMB2 NPHS2
5 sporadic idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis 33.5 PLCE1 WT1
6 nephrotic syndrome, type 6 33.5 ARHGDIA EMP2 NPHS1 NPHS2 NUP93 PLCE1
7 galloway-mowat syndrome 33.2 NPHS1 NPHS2 NUP107
8 familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 32.8 COQ8B NPHS1 NPHS2 NUP107 NUP205 NUP93
9 hypoparathyroidism, sensorineural deafness, and renal disease 32.6 LAMB2 NPHS1 NPHS2
10 denys-drash syndrome 32.6 NPHS1 NPHS2 WT1
11 membranous nephropathy 32.5 ALB B2M NPHS1 NPHS2
12 frasier syndrome 32.4 NPHS1 NPHS2 PLCE1 WT1
13 focal segmental glomerulosclerosis 32.3 ALB COQ6 LAMB2 NPHS1 NPHS2 NUP107
14 diffuse mesangial sclerosis 32.0 ARHGDIA LAMB2 NPHS1 NPHS2 PLCE1 WT1
15 kidney disease 31.9 ALB B2M NPHS1 NPHS2 WT1
16 glomerulonephritis 31.1 ALB NPHS1 NPHS2
17 iga glomerulonephritis 30.5 ALB NPHS1 NPHS2
18 chronic kidney failure 30.1 ALB B2M NPHS1 NPHS2 WT1
19 amyloidosis aa 30.0 APOA1 B2M
20 crescentic glomerulonephritis 29.8 NPHS2 PTPRO WT1
21 wilms tumor 1 29.7 NPHS1 NPHS2 PTPRO WT1
22 familial lcat deficiency 29.6 ALB APOA1
23 diffuse glomerulonephritis 29.5 ALB B2M
24 danubian endemic familial nephropathy 29.4 ALB B2M
25 nephrotic syndrome, type 5, with or without ocular abnormalities 12.5
26 nephrotic syndrome, type 2 12.5
27 nephrotic syndrome, type 3 12.5
28 congenital nephrotic syndrome finnish type 12.4
29 nephrotic syndrome, type 7 12.4
30 nephrotic syndrome, type 14 12.4
31 interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital 12.4
32 nephrotic syndrome, type 4 12.4
33 nephrotic syndrome, type 9 12.4
34 nephrotic syndrome, type 12 12.3
35 nephrotic syndrome, type 15 12.3
36 nephrotic syndrome, type 8 12.3
37 nephrotic syndrome, type 11 12.3
38 nephrotic syndrome, type 10 12.3
39 nephrotic syndrome, type 16 12.3
40 nephrotic syndrome, type 13 12.3
41 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 12.1
42 idiopathic steroid-sensitive nephrotic syndrome with focal segmental hyalinosis 12.1
43 nephrotic syndrome, idiopathic, steroid-resistant 12.1
44 sporadic idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation 12.1
45 sporadic idiopathic steroid-resistant nephrotic syndrome with minimal changes 12.1
46 idiopathic steroid-sensitive nephrotic syndrome with minimal change 12.1
47 idiopathic steroid-sensitive nephrotic syndrome with diffuse mesangial proliferation 12.1
48 sporadic idiopathic steroid-resistant nephrotic syndrome with collapsing glomerulopathy 12.1
49 nephrotic syndrome ocular anomalies 12.0
50 leigh syndrome with nephrotic syndrome 12.0

Graphical network of the top 20 diseases related to Nephrotic Syndrome:



Diseases related to Nephrotic Syndrome
Sources

Symptoms & Phenotypes for Nephrotic Syndrome

About this section

UMLS symptoms related to Nephrotic Syndrome:


edema

MGI Mouse Phenotypes related to Nephrotic Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 APOA1 ARHGDIA B2M EMP2 ITGA3 MAGI2
2 homeostasis/metabolism MP:0005376 10 ALB APOA1 ARHGDIA B2M COQ6 ITGA3
3 mortality/aging MP:0010768 9.73 ALB ARHGDIA B2M COQ6 ITGA3 LAMB2
4 renal/urinary system MP:0005367 9.36 ALB ARHGDIA ITGA3 LAMB2 MAGI2 NPHS1
Sources

Drugs & Therapeutics for Nephrotic Syndrome

About this section

Drugs for Nephrotic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
7
rituximab Approved Phase 4,Phase 2,Phase 3 174722-31-7 10201696
8
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
9
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
10
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
11
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
13
Pravastatin Approved Phase 4,Phase 1 81093-37-0 54687
14
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
15
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
16
Ergocalciferol Approved, Nutraceutical Phase 4,Not Applicable 50-14-6 5280793
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
18
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 5280795 6221
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
20
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
21
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
22
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
23 Tocotrienol Investigational Phase 4 6829-55-6
24 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
26 Prednisolone acetate Phase 4,Phase 3,Phase 2,Not Applicable
27 Vaccines Phase 4
28 Cyclosporins Phase 4,Phase 2
29 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
37 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
38 Protective Agents Phase 4,Phase 3,Not Applicable
39 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
40 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
42 diuretics Phase 4,Phase 3
43 Natriuretic Agents Phase 4,Phase 3
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Bone Density Conservation Agents Phase 4,Phase 3,Not Applicable
46 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
47 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
50 Anticholesteremic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 131)
# Name Status NCT ID Phase Drugs
1 Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
2 Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
3 Long Term Tapering or Standard Steroids for Nephrotic Syndrome Unknown status NCT00308321 Phase 4 long term tapering of prednisolone;standard prednisolone treatment
4 Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children Completed NCT01162005 Phase 4 Tacrolimus
5 Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Completed NCT01895894 Phase 4 Mycophenolate mofetil
6 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
7 A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
8 Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study Completed NCT01185197 Phase 4 Myfortic plus low-dose steroid;Prednisolone
9 Pharmacokinetics of Tacrolimus in Children Completed NCT03347357 Phase 4 Tacrolimus
10 Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes Completed NCT01021540 Phase 4 Repository corticotrophin
11 Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema Completed NCT02427880 Phase 4 Acetazolamide and Hydrochlorothiazide Followed by Furosemide;Furosemide and Hydrochlorothiazide Followed by Furosemide
12 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
13 Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) Completed NCT01028287 Phase 4 ACTH;ACTH
14 Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Completed NCT02238418 Phase 4 Cholecalciferol vial (100 000 UI)
15 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
16 Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome Recruiting NCT02382575 Phase 4 Rituximab;Tacrolimus
17 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease Recruiting NCT00982072 Phase 4 tacrolimus;prednisolone
18 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
19 Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy Recruiting NCT03210688 Phase 4 Prednisolone;Alfacalcidol
20 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
21 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Active, not recruiting NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
22 Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome Not yet recruiting NCT02649413 Phase 4 Prednisone
23 ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children Not yet recruiting NCT03408405 Phase 4 Acthar Gel 80 UNT/ML Injectable Solution
24 Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study Terminated NCT00384618 Phase 4 pravastatin;vitamin E
25 Rituximab Trial for Pediatric Nephrotic Syndrome Unknown status NCT01716442 Phase 2, Phase 3 Rituximab;Placebo
26 Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy Unknown status NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
27 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome Completed NCT02132195 Phase 3 ACTH
28 Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood Completed NCT01268033 Phase 2, Phase 3 Rituximab;Placebo
29 Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children Completed NCT01092962 Phase 3 Cyclophosphamide;Mycophenolate mofetil
30 Efficacy of Pentoxifylline on Primary Nephrotic Syndrome Completed NCT00354731 Phase 3 pentoxifylline;Corticosteroid
31 Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome Completed NCT02438982 Phase 3 Tacrolimus;Rituximab
32 A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome Completed NCT02257697 Phase 3 Mizoribine (MZR);Cyclophosphamide (CTX)
33 Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome Completed NCT01197040 Phase 3 Prednisone;acid mycophenolic (Myfortic)
34 The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS) Completed NCT01309477 Phase 3 Tacrolimus Sustained-release Capsules (ADVAGRAF)
35 Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
36 Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS) Completed NCT00615667 Phase 3 tacrolimus (FK506)
37 Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00981838 Phase 3 Rituximab
38 Steroid Treatment for Kidney Disease Completed NCT00065611 Phase 3 Oral dexamethasone
39 Rituximab in Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
40 Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
41 Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Completed NCT01084980 Phase 2, Phase 3 Tacrolimus
42 Prednisolone Trial in Children Younger Than 4 Years Recruiting NCT03141970 Phase 3 Prednisolone
43 Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome Recruiting NCT03501459 Phase 3 Rituximab
44 Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children Recruiting NCT02818738 Phase 3 Levamisole Hydrochloride
45 Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Recruiting NCT03298698 Phase 3 Rituximab;Prednisone
46 Valproic Acid for Idiopathic Nephrotic Syndrome Recruiting NCT02896270 Phase 2, Phase 3 Valproic Acid
47 Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
48 Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome Not yet recruiting NCT03560011 Phase 2, Phase 3 immunoglobulin IV
49 Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome Terminated NCT02390362 Phase 3 Rituximab;MMF
50 IL-2 for Multi Drug Resistant Nephrotic Syndrome Completed NCT02455908 Phase 1, Phase 2 Proleukin®

Search NIH Clinical Center for Nephrotic Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: nephrotic syndrome

Sources

Genetic Tests for Nephrotic Syndrome

About this section

Genetic tests related to Nephrotic Syndrome:

# Genetic test Affiliating Genes
1 Nephrotic Syndrome 29
Sources

Anatomical Context for Nephrotic Syndrome

About this section

MalaCards organs/tissues related to Nephrotic Syndrome:

41
Kidney, Testes, Bone, T Cells, Liver, Thyroid, Endothelial
Sources

Publications for Nephrotic Syndrome

About this section

Articles related to Nephrotic Syndrome:

(show top 50) (show all 3143)
# Title Authors Year
1
Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. ( 30141179 )
2019
2
B cell phenotype in pediatric idiopathic nephrotic syndrome. ( 30267238 )
2019
3
Nephrotic Syndrome. ( 30454752 )
2019
4
Nephrotic syndrome complicated with femoral vein catheter-related phlegmasia cerulea dolens: A case report. ( 29436096 )
2018
5
Levamisole in relapsing steroid-sensitive nephrotic syndrome: where do we stand? ( 29389398 )
2018
6
Adrenocortical Suppression in Children with Nephrotic Syndrome Treated with Low-Dose Alternate Day Corticosteroids. ( 29962670 )
2018
7
Pulmonary Thromboembolism: A Rare but Serious Complication of Nephrotic Syndrome. ( 29962680 )
2018
8
Serum sickness with refractory nephrotic syndrome following treatment with rituximab. ( 29305810 )
2018
9
Chlormethine Hydrochloride is Not Inferior to Tacrolimus in Treating Steroid-Resistant Nephrotic Syndrome. ( 29402844 )
2018
10
Low birth weight is a conditioning factor for podocyte alteration and steroid dependance in children with nephrotic syndrome. ( 29350347 )
2018
11
Nail-Patella Syndrome: A Rare Cause of Nephrotic Syndrome in Pregnancy. ( 29515307 )
2018
12
Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome. ( 29421774 )
2018
13
Acute kidney injury complicating nephrotic syndrome of minimal change disease. ( 29980292 )
2018
14
Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome. ( 29426974 )
2018
15
Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study. ( 29399079 )
2018
16
Spontaneous remission of adult-onset minimal change nephrotic syndrome associated with influenza B infection: a case report. ( 29973143 )
2018
17
Allergic bronchopulmonary aspergillosis presenting as nephrotic syndrome due to secondary amyloidosis: Case report and systematic review of the literature. ( 29970774 )
2018
18
Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome. ( 29436729 )
2018
19
Should antiviral monotherapy with nucleotide analogs be the primary treatment option for focal segmental glomerulosclerosis-related nephrotic syndrome in chronic hepatitis B infection? ( 29970751 )
2018
20
Liddle's-like syndrome associated with nephrotic syndrome secondary to membranous nephropathy: the first case report. ( 29792170 )
2018
21
Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy. ( 29568223 )
2018
22
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report andA review of the literaturea8c. ( 29393843 )
2018
23
Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome? ( 29959531 )
2018
24
Azithromycin suppressed relapses of idiopathic nephrotic syndrome in a child. ( 29423202 )
2018
25
Serial Manifestation of Acute Kidney Injury and Nephrotic Syndrome in a Patient with TAFRO syndrome. ( 29877281 )
2018
26
BehAset's syndrome and focal segmental glomerulosclerosis with nephrotic syndrome - successful treatment with etanercepta8c. ( 29292692 )
2018
27
Plasma Cell Leukemia Masquerading as a Relapse of the Nephrotic Syndrome. ( 29401321 )
2018
28
Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy. ( 29395322 )
2018
29
Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report. ( 29939487 )
2018
30
Evaluation of interleukin-18 in children with steroid-sensitive nephrotic syndrome before and after using levamisole. ( 29970735 )
2018
31
Can Focal Segmental Glomerulosclerosis Be Differentiated From Minimal Change Nephrotic Syndrome Using Biomarkers? ( 29661342 )
2018
32
Lemmings into the sea or back across the bridge? The fate of albumin in nephrotic syndrome. ( 29389392 )
2018
33
Histopathological study of nephrotic syndrome in adults: A Moroccan report. ( 29970742 )
2018
34
<i>GAPVD1</i> and <i>ANKFY1</i> Mutations Implicate RAB5 Regulation in Nephrotic Syndrome. ( 29959197 )
2018
35
Correlation Between Single-Nucleotide Polymorphisms Within miR-30a and Related Target Genes and Risk or Prognosis of Nephrotic Syndrome. ( 29356585 )
2018
36
Persistent hypoglycemic attacks during hemodialysis sessions in an infant with congenital nephrotic syndrome: Questions. ( 29959530 )
2018
37
Successful treatment of rituximab- and steroid-resistant nephrotic syndrome with leukocytapheresis. ( 29341230 )
2018
38
Cytotoxic T- Lymphocyte Antigen-4 (CTLA4) Gene Expression and Urinary CTLA4 Levels in Idiopathic Nephrotic Syndrome. ( 29968132 )
2018
39
Nephrotic syndrome in very elderly: Should we treat aggressively? ( 29441190 )
2018
40
Persistent hypoglycemic attacks during hemodialysis sessions in an infant with congenital nephrotic syndrome: Answers. ( 29959533 )
2018
41
IL-23 Activated I^I' T Cells Affect Th17 Cells and Regulatory T Cells by Secreting IL-21 in Children with Primary Nephrotic Syndrome. ( 29119640 )
2018
42
Cryptococcosis as a cause of nephrotic syndrome? A case report and review of the literature. ( 29942774 )
2018
43
Predictors of poor outcome in children with steroid sensitive nephrotic syndrome. ( 29429831 )
2018
44
Portal Vein Thrombosis: A Rare Complication of Nephrotic Syndrome. ( 29962677 )
2018
45
Amyloidosis: a unifying diagnosis for nephrotic syndrome and congestive cardiac failure. ( 30150332 )
2018
46
Complete remission of nephrotic syndrome secondary to amyloid a amyloidosis in patient with inactive Crohn's disease after treatment by infliximab. ( 29657220 )
2018
47
C1q nephropathy among children with nephrotic syndrome: Ten-year experience from a pediatric nephrology unit. ( 30102475 )
2018
48
Cardiac arrest from massive PE in nephrotic syndrome successfully treated with embolectomy and ECMO. ( 29984150 )
2018
49
Chronic thromboembolic pulmonary hypertension as the first manifestation of nephrotic syndrome in a 12-year-old child. ( 30313030 )
2018
50
Crohn's disease following rituximab treatment in a patient with refractory nephrotic syndrome. ( 30251194 )
2018
Sources

Variations for Nephrotic Syndrome

About this section

ClinVar genetic disease variations for Nephrotic Syndrome:

6 (show top 50) (show all 320)
# Gene Variation Type Significance SNP ID Assembly Location
1 TRPC6 NM_004621.5(TRPC6): c.523C> T (p.Arg175Trp) single nucleotide variant Uncertain significance rs869025541 GRCh38 Chromosome 11, 101504446: 101504446
2 TRPC6 NM_004621.5(TRPC6): c.523C> T (p.Arg175Trp) single nucleotide variant Uncertain significance rs869025541 GRCh37 Chromosome 11, 101375177: 101375177
3 LAMB2 NM_002292.3(LAMB2): c.5293G> A (p.Ala1765Thr) single nucleotide variant Benign/Likely benign rs74951356 GRCh38 Chromosome 3, 49121330: 49121330
4 LAMB2 NM_002292.3(LAMB2): c.5293G> A (p.Ala1765Thr) single nucleotide variant Benign/Likely benign rs74951356 GRCh37 Chromosome 3, 49158763: 49158763
5 LAMB2 NM_002292.3(LAMB2): c.4878G> A (p.Arg1626=) single nucleotide variant Conflicting interpretations of pathogenicity rs148648480 GRCh37 Chromosome 3, 49159422: 49159422
6 LAMB2 NM_002292.3(LAMB2): c.4878G> A (p.Arg1626=) single nucleotide variant Conflicting interpretations of pathogenicity rs148648480 GRCh38 Chromosome 3, 49121989: 49121989
7 LAMB2 NM_002292.3(LAMB2): c.4774C> T (p.Arg1592Trp) single nucleotide variant Benign/Likely benign rs61729458 GRCh38 Chromosome 3, 49122170: 49122170
8 LAMB2 NM_002292.3(LAMB2): c.4774C> T (p.Arg1592Trp) single nucleotide variant Benign/Likely benign rs61729458 GRCh37 Chromosome 3, 49159603: 49159603
9 LAMB2 NM_002292.3(LAMB2): c.4034G> A (p.Arg1345His) single nucleotide variant Conflicting interpretations of pathogenicity rs75073433 GRCh37 Chromosome 3, 49160755: 49160755
10 LAMB2 NM_002292.3(LAMB2): c.4034G> A (p.Arg1345His) single nucleotide variant Conflicting interpretations of pathogenicity rs75073433 GRCh38 Chromosome 3, 49123322: 49123322
11 LAMB2 NM_002292.3(LAMB2): c.3387A> G (p.Gln1129=) single nucleotide variant Benign/Likely benign rs34290943 GRCh37 Chromosome 3, 49161660: 49161660
12 LAMB2 NM_002292.3(LAMB2): c.3387A> G (p.Gln1129=) single nucleotide variant Benign/Likely benign rs34290943 GRCh38 Chromosome 3, 49124227: 49124227
13 LAMB2 NM_002292.3(LAMB2): c.2959G> A (p.Glu987Lys) single nucleotide variant Benign/Likely benign rs34759087 GRCh37 Chromosome 3, 49162284: 49162284
14 LAMB2 NM_002292.3(LAMB2): c.2959G> A (p.Glu987Lys) single nucleotide variant Benign/Likely benign rs34759087 GRCh38 Chromosome 3, 49124851: 49124851
15 LAMB2 NM_002292.3(LAMB2): c.2740G> A (p.Gly914Arg) single nucleotide variant Benign/Likely benign rs35713889 GRCh38 Chromosome 3, 49125150: 49125150
16 LAMB2 NM_002292.3(LAMB2): c.2740G> A (p.Gly914Arg) single nucleotide variant Benign/Likely benign rs35713889 GRCh37 Chromosome 3, 49162583: 49162583
17 LAMB2 NM_002292.3(LAMB2): c.1764C> T (p.Pro588=) single nucleotide variant Benign/Likely benign rs33942096 GRCh38 Chromosome 3, 49128787: 49128787
18 LAMB2 NM_002292.3(LAMB2): c.1764C> T (p.Pro588=) single nucleotide variant Benign/Likely benign rs33942096 GRCh37 Chromosome 3, 49166220: 49166220
19 LAMB2 NM_002292.3(LAMB2): c.1206G> A (p.Arg402=) single nucleotide variant Conflicting interpretations of pathogenicity rs201999373 GRCh38 Chromosome 3, 49130250: 49130250
20 LAMB2 NM_002292.3(LAMB2): c.1206G> A (p.Arg402=) single nucleotide variant Conflicting interpretations of pathogenicity rs201999373 GRCh37 Chromosome 3, 49167683: 49167683
21 LAMB2 NM_002292.3(LAMB2): c.1193C> T (p.Thr398Ile) single nucleotide variant Benign/Likely benign rs77500937 GRCh37 Chromosome 3, 49167696: 49167696
22 LAMB2 NM_002292.3(LAMB2): c.1193C> T (p.Thr398Ile) single nucleotide variant Benign/Likely benign rs77500937 GRCh38 Chromosome 3, 49130263: 49130263
23 LAMB2 NM_002292.3(LAMB2): c.306C> T (p.Asn102=) single nucleotide variant Benign/Likely benign rs79448908 GRCh37 Chromosome 3, 49169782: 49169782
24 LAMB2 NM_002292.3(LAMB2): c.306C> T (p.Asn102=) single nucleotide variant Benign/Likely benign rs79448908 GRCh38 Chromosome 3, 49132349: 49132349
25 PLCE1 NM_016341.3(PLCE1): c.513G> A (p.Val171=) single nucleotide variant Conflicting interpretations of pathogenicity rs61749239 GRCh38 Chromosome 10, 94031559: 94031559
26 PLCE1 NM_016341.3(PLCE1): c.513G> A (p.Val171=) single nucleotide variant Conflicting interpretations of pathogenicity rs61749239 GRCh37 Chromosome 10, 95791316: 95791316
27 PLCE1 NM_016341.3(PLCE1): c.810T> C (p.Cys270=) single nucleotide variant Benign rs17109671 GRCh38 Chromosome 10, 94031856: 94031856
28 PLCE1 NM_016341.3(PLCE1): c.810T> C (p.Cys270=) single nucleotide variant Benign rs17109671 GRCh37 Chromosome 10, 95791613: 95791613
29 PLCE1 NM_016341.3(PLCE1): c.960G> A (p.Glu320=) single nucleotide variant Benign rs17109674 GRCh37 Chromosome 10, 95791763: 95791763
30 PLCE1 NM_016341.3(PLCE1): c.960G> A (p.Glu320=) single nucleotide variant Benign rs17109674 GRCh38 Chromosome 10, 94032006: 94032006
31 PLCE1 NM_016341.3(PLCE1): c.1405T> A (p.Ser469Thr) single nucleotide variant Benign/Likely benign rs17508082 GRCh37 Chromosome 10, 95892129: 95892129
32 PLCE1 NM_016341.3(PLCE1): c.1405T> A (p.Ser469Thr) single nucleotide variant Benign/Likely benign rs17508082 GRCh38 Chromosome 10, 94132372: 94132372
33 PLCE1 NM_016341.3(PLCE1): c.1643G> T (p.Arg548Leu) single nucleotide variant Benign rs17417407 GRCh38 Chromosome 10, 94171330: 94171330
34 PLCE1 NM_016341.3(PLCE1): c.1643G> T (p.Arg548Leu) single nucleotide variant Benign rs17417407 GRCh37 Chromosome 10, 95931087: 95931087
35 PLCE1 NM_016341.3(PLCE1): c.1729G> A (p.Ala577Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs141639885 GRCh37 Chromosome 10, 95931173: 95931173
36 PLCE1 NM_016341.3(PLCE1): c.1729G> A (p.Ala577Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs141639885 GRCh38 Chromosome 10, 94171416: 94171416
37 PLCE1 NM_016341.3(PLCE1): c.2124G> A (p.Val708=) single nucleotide variant Benign/Likely benign rs61751496 GRCh38 Chromosome 10, 94234222: 94234222
38 PLCE1 NM_016341.3(PLCE1): c.2124G> A (p.Val708=) single nucleotide variant Benign/Likely benign rs61751496 GRCh37 Chromosome 10, 95993979: 95993979
39 PLCE1 NM_016341.3(PLCE1): c.3132C> T (p.His1044=) single nucleotide variant Benign/Likely benign rs61732522 GRCh37 Chromosome 10, 96012108: 96012108
40 PLCE1 NM_016341.3(PLCE1): c.3132C> T (p.His1044=) single nucleotide variant Benign/Likely benign rs61732522 GRCh38 Chromosome 10, 94252351: 94252351
41 PLCE1 NM_016341.3(PLCE1): c.4059C> T (p.Phe1353=) single nucleotide variant Benign/Likely benign rs61751499 GRCh37 Chromosome 10, 96025409: 96025409
42 PLCE1 NM_016341.3(PLCE1): c.4059C> T (p.Phe1353=) single nucleotide variant Benign/Likely benign rs61751499 GRCh38 Chromosome 10, 94265652: 94265652
43 PLCE1 NM_016341.3(PLCE1): c.4263G> A (p.Ser1421=) single nucleotide variant Benign/Likely benign rs41291134 GRCh38 Chromosome 10, 94265940: 94265940
44 PLCE1 NM_016341.3(PLCE1): c.4263G> A (p.Ser1421=) single nucleotide variant Benign/Likely benign rs41291134 GRCh37 Chromosome 10, 96025697: 96025697
45 PLCE1 NM_016341.3(PLCE1): c.4724G> C (p.Arg1575Pro) single nucleotide variant Benign rs2274224 GRCh38 Chromosome 10, 94279840: 94279840
46 PLCE1 NM_016341.3(PLCE1): c.4724G> C (p.Arg1575Pro) single nucleotide variant Benign rs2274224 GRCh37 Chromosome 10, 96039597: 96039597
47 PLCE1 NM_016341.3(PLCE1): c.5035+12C> A single nucleotide variant Benign rs3736901 GRCh38 Chromosome 10, 94284977: 94284977
48 PLCE1 NM_016341.3(PLCE1): c.5035+12C> A single nucleotide variant Benign rs3736901 GRCh37 Chromosome 10, 96044734: 96044734
49 PLCE1 NM_016341.3(PLCE1): c.5330C> T (p.Thr1777Ile) single nucleotide variant Benign rs3765524 GRCh38 Chromosome 10, 94298541: 94298541
50 PLCE1 NM_016341.3(PLCE1): c.5330C> T (p.Thr1777Ile) single nucleotide variant Benign rs3765524 GRCh37 Chromosome 10, 96058298: 96058298
Sources

Expression for Nephrotic Syndrome

About this section
Search GEO for disease gene expression data for Nephrotic Syndrome.
Sources

Pathways for Nephrotic Syndrome

About this section

Pathways related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Interferon gamma signaling 66
Show member pathways
 11.95 B2M NUP107 NUP205 NUP93
2
Hexose transport 66
Show member pathways
 11.13 NUP107 NUP205 NUP93
3
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.09 ITGA3 LAMB2 NPHS1 NPHS2 PLCE1 PTPRO
4
Nephrin interactions 66
10.6 MAGI2 NPHS1
Sources

GO Terms for Nephrotic Syndrome

About this section

Cellular components related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 ALB APOA1 ARHGDIA B2M ITGA3 LAMB2
2 endoplasmic reticulum lumen GO:0005788 9.71 ALB APOA1 B2M LAMB2
3 nuclear pore GO:0005643 9.43 NUP107 NUP205 NUP93
4 extrinsic component of mitochondrial inner membrane GO:0031314 9.32 COQ6 COQ8B
5 nuclear periphery GO:0034399 9.13 NUP107 NUP205 NUP93
6 slit diaphragm GO:0036057 8.8 MAGI2 NPHS1 NPHS2
7 membrane GO:0016020 10.24 ARHGDIA B2M COQ6 COQ8B EMP2 ITGA3

Biological processes related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.73 ALB APOA1 B2M LAMB2
2 mRNA transport GO:0051028 9.7 NUP107 NUP205 NUP93
3 mRNA export from nucleus GO:0006406 9.69 NUP107 NUP205 NUP93
4 female gonad development GO:0008585 9.56 NUP107 SGPL1
5 adrenal gland development GO:0030325 9.55 APOA1 WT1
6 high-density lipoprotein particle remodeling GO:0034375 9.54 ALB APOA1
7 nucleocytoplasmic transport GO:0006913 9.5 NUP107 NUP205 NUP93
8 ubiquinone biosynthetic process GO:0006744 9.49 COQ6 COQ8B
9 blood vessel endothelial cell migration GO:0043534 9.48 APOA1 EMP2
10 glomerular basement membrane development GO:0032836 9.46 NPHS1 WT1
11 glomerular visceral epithelial cell differentiation GO:0072112 9.4 PTPRO WT1
12 regulation of glomerular filtration GO:0003093 9.37 EMP2 PTPRO
13 nuclear pore complex assembly GO:0051292 9.33 NUP107 NUP205 NUP93
14 metanephric glomerular visceral epithelial cell development GO:0072249 9.26 LAMB2 NPHS2
15 glomerulus development GO:0032835 9.13 PLCE1 PTPRO WT1
16 glomerular visceral epithelial cell development GO:0072015 8.8 MAGI2 NPHS1 NUP93

Molecular functions related to Nephrotic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 ALB APOA1 ARHGDIA B2M COQ6 EMP2
2 integrin binding GO:0005178 9.33 EMP2 ITGA3 LAMB2
3 structural constituent of nuclear pore GO:0017056 9.13 NUP107 NUP205 NUP93
Sources

Sources for Nephrotic Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....